Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XNW34017 in Advanced Solid Tumors
NCT07327294Phase 2Not yet recruiting
- Sponsor
- Evopoint Biosciences
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
A Phase 2 trial of XNW34017 in solid tumor (advanced stage), small cell lung cancer (SCLC), prostate cancer (PCa), sponsored by Evopoint Biosciences. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
XNW34017
03
Conditions
solid tumor (advanced stage)small cell lung cancer (SCLC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07327294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07327294.